Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

ALS data comp: Clene’s NfL reduction vs. Biogen’s

As Clene explores NDA submission, BioCentury benchmarks its NfL data against that of the sole ALS drug with accelerated approval

June 16, 2023 9:10 PM UTC

When Clene’s therapy missed the primary endpoint in the HEALEY ALS platform trial, HEALEY Director Merit Cudkowicz argued that the results of a prespecified survival analysis warranted additional study of the drug. With Thursday’s announcement that CNM-Au8 had a statistically significant effect on plasma NfL in the platform study, the question now is whether the additional study could be pushed to the postmarket setting.

In light of the NfL readout, which comes nine months after the primary endpoint results were reported, the Clene Nanomedicine unit of  Clene Inc. (NASDAQ:CLNN) said it is “exploring the possibility for a NDA filing” for CNM-Au8 based on the biomarker...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.

Clene Inc.

BCIQ Target Profiles

Superoxide dismutase 1 (SOD1)